ProfileGDS5678 / 1449950_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 53% 53% 51% 51% 54% 51% 56% 53% 53% 53% 53% 52% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3225552
GSM967853U87-EV human glioblastoma xenograft - Control 23.304453
GSM967854U87-EV human glioblastoma xenograft - Control 33.310453
GSM967855U87-EV human glioblastoma xenograft - Control 43.1752151
GSM967856U87-EV human glioblastoma xenograft - Control 53.1878651
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4437654
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3250651
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4004156
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2793153
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2962853
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2900653
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2505653
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2777452
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2977253